Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis
Tapinarof was well tolerated and resulted in high skin clearance rates that were maintained off-therapy and consistent safety in patients down to age 2 years.
Authors
- Eric L. Simpson (ORCID: https://orcid.org/0000-0003-0853-0252)
- Robert Bissonnette (ORCID: https://orcid.org/0000-0001-5927-6587)
- John Browning (ORCID: https://orcid.org/0000-0002-3708-2252)
- Andrew F Alexis (ORCID: https://orcid.org/0000-0002-1351-9165)
- Philip M. Brown
- Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
- Leon Kircik (ORCID: https://orcid.org/0000-0002-0831-2151)
- David S. Rubenstein (ORCID: https://orcid.org/0000-0003-0302-8722)
- Stephen C. Piscitelli (ORCID: https://orcid.org/0000-0002-4528-3273)
- Lawrence F. Eichenfield (ORCID: https://orcid.org/0000-0002-2760-0474)
- Anna M. Tallman (ORCID: https://orcid.org/0000-0001-9535-0414)
- Adelaide A. Hebert (ORCID: https://orcid.org/0000-0002-9167-5729)
- Weily Soong (ORCID: https://orcid.org/0000-0002-2701-7035)
- Jonathan I. Silverberg
Institutions
- Alabama Department of Public Health (US)
- Memorial Hermann (US)
- Henry Ford Health System (US)
- Oregon Health & Science University (US)
- George Washington University (US)
- Cornell University (US)
- University of California San Diego (US)
- Rady Children's Hospital-San Diego (US)
- Texas Dermatology and Laser Specialists (US)
- Roivant Sciences (United States) (US)
- Weill Cornell Medicine (US)
- The University of Texas Health Science Center at Houston (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1016/j.jaad.2025.05.1391
- Citations
- 5
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 10.02